Xavier Leleu, MD, PhD, is Professor, Head of the myeloma clinic and head of the department of Haematology at *Hôpital La Mileterie*, part of the academic hospital of Poitiers (CHU), France. Dr Leleu received his medical degree at the University of Bordeaux, France. He completed specialization in public healthcare and statistics at the University of Medicine of Paris, France and in haematology at the University of Medicine of Lille. Dr leleu was the head of the Myeloma clinic in Lille under Pr T Facon mentorship for almost 15 years. He received a Master's in cellular biology at the University of Medicine of Lille in 2001 and completed his PhD in 2007 having done his research at Dana-Farber Cancer Institute, affiliated with Harvard Medical School, Boston, MA, USA. His main topic of research was the preclinical development of the novel agent and understanding mechanisms of resistance and of dormancy in Waldenström macroglobulinaemia and the clinical development of novel agents in multiple myeloma in the context of the most recent discovery in the biology of myeloma. He was trained with his mentors Dr IM Ghobrial and Dr SP Treon in Prof. Kenneth Anderson's laboratory.

Doctor Leleu's research is focused on the biology and treatment of multiple myeloma, Waldenstrom's macroglobulinemia and amyloidosis and he has published widely in the area.

He is actively involved in numerous national and international clinical trials as investigator and coordinator. Professor Leleu is a frequent speaker at national and international congresses and is a reviewer or a member of the editorial board of several hematology journals. He is actively involved in the Intergroupe Francophone du Myélome (IFM), currently in the board of directors, and is also a member of a number of other national and international scientific societies.